Emergence of the concept of platelet reactivity monitoring of response to thienopyridines

被引：18

作者：

Bonello, L. ^{[1
,2
,3
]}

De Labriolle, A. ^{[1
]}

Scheinowitz, M. ^{[1
]}

Lemesle, G. ^{[4
,5
]}

Roy, P. ^{[1
]}

Steinberg, D. H. ^{[1
]}

Slottow, T. L. Pinto ^{[1
]}

Pakala, R. ^{[1
]}

Pichard, A. D. ^{[1
]}

Barragan, P. ^{[6
]}

Camoin-Jau, L. ^{[3
]}

Dignat-George, F. ^{[3
]}

Paganelli, F. ^{[2
]}

Waksman, R. ^{[1
]}

机构：

[1] Washington Hosp Ctr, Dept Internal Med, Div Cardiol, Washington, DC 20010 USA

[2] Hop Univ Nord Marseille, Dept Cardiol, Marseille, France

[3] Hop Conception, INSERM, UMRS 608, UFR Pharm,Lab Hematol, Marseille, France

[4] Ctr Hosp Reg & Univ Lille, Hop Cardiol, Serv Cardiol B, F-59037 Lille, France

[5] Ctr Hosp Reg & Univ Lille, Hop Cardiol, Ctr Hemodynam, F-59037 Lille, France

[6] Clin Fleurs, Dept Cardiol, Ollioules, France

来源：

HEART | 2009年 / 95卷 / 15期

关键词：

VASODILATOR-STIMULATED PHOSPHOPROTEIN; PERCUTANEOUS CORONARY INTERVENTION; INTRAPLATELET VASP PHOSPHORYLATION; ADVERSE CARDIOVASCULAR EVENTS; FLOW-CYTOMETRIC ANALYSIS; STENT THROMBOSIS; CLOPIDOGREL RESISTANCE; ANTIPLATELET THERAPY; CLINICAL-OUTCOMES; ARTERY-DISEASE;

D O I：

10.1136/hrt.2008.152660

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Clinical trials have demonstrated the beneficial impact of clopidogrel in preventing major adverse cardiovascular events (MACE), particularly in patients undergoing percutaneous coronary intervention (PCI). The concept of biological clopidogrel resistance emerged with the finding of persistent platelet activation despite clopidogrel therapy in some patients. Further, a link between biological clopidogrel resistance and thrombotic recurrence after PCI was observed and a threshold of platelet reactivity (PR) for thrombotic events was suggested. Consistently, in recent trials, enhanced PR inhibition translated into a reduction in the rate of MACE after PCI. This review aims to present the emergence of the concept of PR monitoring in patients undergoing PCI following recent advances in this field.

引用

页码：1214 / 1219

页数：6

共 33 条

[21] Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug [J].

Labarthe, B ;

Théroux, P ;

Angioï, M ;

Ghitescu, M .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (04) :638-645

[22] Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study [J].

Mehta, SR ;

Yusuf, S ;

Peters, RJG ;

Bertrand, ME ;

Lewis, BS ;

Natarajan, MK ;

Maimberg, K ;

Rupprecht, HJ ;

Zhao, F ;

Chrolavicius, S ;

Copland, I ;

Fox, KAA .

LANCET, 2001, 358 (9281) :527-533

[23]

Morel O., 2007, Annales de Cardiologie et d'Angeiologie, V56, P21, DOI 10.1016/j.ancard.2006.11.005

[24] Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation [J].

Moussa, I ;

Oetgen, M ;

Roubin, G ;

Colombo, A ;

Wang, XD ;

Iyer, S ;

Maida, R ;

Collins, M ;

Kreps, E ;

Moses, JW .

CIRCULATION, 1999, 99 (18) :2364-2366

[25] Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients [J].

Paniccia, R. ;

Antonucci, E. ;

Gori, A. M. ;

Marcucci, R. ;

Giglioli, C. ;

Antoniucci, D. ;

Gensini, G. F. ;

Abbate, R. ;

Prisco, D. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (09) :1839-1847

[26] Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention - Results from the ARMYDA-2 (Antiplatelet therapy for reduction of MYocardial Damage during Angioplasty) study [J].

Patti, G ;

Colonna, G ;

Pasceri, V ;

Pepe, LL ;

Montinaro, A ;

Di Sciascio, G .

CIRCULATION, 2005, 111 (16) :2099-2106

[27] Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation [J].

Price, Matthew J. ;

Endemann, Sarah ;

Gollapudi, Raghava R. ;

Valencia, Rafael ;

Stinis, Curtiss T. ;

Levisay, Justin P. ;

Ernst, Alissa ;

Sawhney, Neil S. ;

Schatz, Richard A. ;

Teirstein, Paul S. .

EUROPEAN HEART JOURNAL, 2008, 29 (08) :992-1000

[28] The difference between clopidogrel responsiveness and posttreatment platelet reactivity [J].

Samara, WM ;

Bliden, KP ;

Tantry, US ;

Gurbel, PA .

THROMBOSIS RESEARCH, 2005, 115 (1-2) :89-94

[29] CLINICAL-EXPERIENCE WITH THE PALMAZ-SCHATZ CORONARY STENT - INITIAL RESULTS OF A MULTICENTER STUDY [J].

SCHATZ, RA ;

BAIM, DS ;

LEON, M ;

ELLIS, SG ;

GOLDBERG, S ;

HIRSHFELD, JW ;

CLEMAN, MW ;

CABIN, HS ;

WALKER, C ;

STAGG, J ;

BUCHBINDER, M ;

TEIRSTEIN, PS ;

TOPOL, EJ ;

SAVAGE, M ;

PEREZ, JA ;

CURRY, RC ;

WHITWORTH, H ;

SOUSA, JE ;

TIO, F ;

ALMAGOR, Y ;

PONDER, R ;

PENN, IM ;

LEONARD, B ;

LEVINE, SL ;

FISH, RD ;

PALMAZ, JC .

CIRCULATION, 1991, 83 (01) :148-161

[30] A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents [J].

Schomig, A ;

Neumann, FJ ;

Kastrati, A ;

Schuhlen, H ;

Blasini, R ;

Hadamitzky, M ;

Walter, H ;

ZitzmannRoth, EM ;

Richardt, G ;

Alt, E ;

Schmitt, C ;

Ulm, K .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (17) :1084-1089

← 1 2 3 4 →